Oxidative Stress in Hemodialysis Patients: Pathophysiological Mechanisms, Clinical Consequences and basic Principles of Treatment

1. Cozzolino M, Mangano M, Stucchi A, et al. (2018). Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 33(1), 28–34. DOI: 10.1093/ndt/gfy174. CozzolinoM ManganoM StucchiA 2018 Cardiovascular disease in dialysis patients Nephrol Dial Transplant. 33 1 28 34 10.1093/ndt/gfy174 Open DOISearch in Google Scholar

2. Zoccali C, Mallamaci F, Tripepi G. (2004). Novel Cardiovascular Risk Factors in End-Stage Renal Disease. J Am Soc Nephrol. 15(Suppl 1), 77–80. DOI: 10.1097/01.ASN.0000093240.84097.FE. ZoccaliC MallamaciF TripepiG 2004 Novel Cardiovascular Risk Factors in End-Stage Renal Disease J Am Soc Nephrol. 15 Suppl 1 77 80 10.1097/01.ASN.0000093240.84097.FE Open DOISearch in Google Scholar

3. Locatelli F, Canaud B, Eckardt K-U, et al. (2003). Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 18(7), 1272–80. DOI: 10.1093/ndt/gfg074. LocatelliF CanaudB Eckardt K-U 2003 Oxidative stress in end-stage renal disease: an emerging threat to patient outcome Nephrol Dial Transplant 18 7 1272 80 10.1093/ndt/gfg074 Open DOISearch in Google Scholar

4. Descamps-Latscha B, Drüeke T, Witko-Sarsat V. (2001). Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial. 14(3), 793–9. DOI: 10.1046/j.1525-139X.2001.00052.x. Descamps-LatschaB DrüekeT Witko-SarsatV 2001 Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy Semin Dial. 14 3 793 9 10.1046/j.1525-139X.2001.00052.x Open DOISearch in Google Scholar

5. Liakopoulos V, Roumeliotis S, Gorny X, et al. (2017). Oxidative Stress in Hemodialysis Patients: A Review of the Literature. Oxidative Med Cell Long. 2017: 3081856., DOI: 10.1155/2017/3081856. LiakopoulosV RoumeliotisS GornyX 2017 Oxidative Stress in Hemodialysis Patients: A Review of the Literature Oxidative Med Cell Long. 2017 3081856 10.1155/2017/3081856 Open DOISearch in Google Scholar

6. Santoro A, Guadagni G. (2010). Dialysis membrane: from convection to adsorption. Nephrol Dial Transplant. 3(Suppl 1), 36–9. DOI: 10.1093/ndtplus/sfg035. SantoroA GuadagniG 2010 Dialysis membrane: from convection to adsorption Nephrol Dial Transplant. 3 Suppl 1 36 9 10.1093/ndtplus/sfg035 Open DOISearch in Google Scholar

7. Ronco C, Clark W. Hemodialysis membranes. (2018). Nat Rev Nephrol. 14(6), 394–410. DOI: 10.1038/s41581-018-0002-x. RoncoC ClarkW Hemodialysis membranes 2018 Nat Rev Nephrol. 14 6 394 410 10.1038/s41581-018-0002-x Open DOISearch in Google Scholar

8. Wu CC, Chen JS, Wu WM, et al. (2005). Myeloperoxidase serves as a marker of oxidative stress during single hemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant. 20(6), 1134–9. DOI: 10.1093/ndt/gfh764. WuCC ChenJS WuWM 2005 Myeloperoxidase serves as a marker of oxidative stress during single hemodialysis session using two different biocompatible dialysis membranes Nephrol Dial Transplant. 20 6 1134 9 10.1093/ndt/gfh764 Open DOISearch in Google Scholar

9. Ward RA. Ultrapure Dialysate. (2004). Semin Dial. 17(6), 489–97. DOI: 10.1111/j.0894-0959.2004.17617.x. WardRA Ultrapure Dialysate 2004 Semin Dial. 17 6 489 97 10.1111/j.0894-0959.2004.17617.x Open DOISearch in Google Scholar

10. Glorieux G, Neirynck N, Veys N, et al. (2012). Dialysis water and fluid purity: more than endotoxin. Nephrol Dial Transplant. 27(11), 4010–21. DOI: 10.1093/ndt/gfs306. GlorieuxG NeirynckN VeysN 2012 Dialysis water and fluid purity: more than endotoxin Nephrol Dial Transplant. 27 11 4010 21 10.1093/ndt/gfs306 Open DOISearch in Google Scholar

11. Aziz MA, Majeed GH, Diab KS, et al. (2016). The association of oxidant-antioxidant status in patients with chronic renal failure. Ren Fail. 38(1), 20–6. DOI: 10.3109/0886022X.2015.1103654. AzizMA MajeedGH DiabKS 2016 The association of oxidant-antioxidant status in patients with chronic renal failure Ren Fail. 38 1 20 6 10.3109/0886022X.2015.1103654 Open DOISearch in Google Scholar

12. Handelman GJ. (2007). Vitamin C deficiency in dialysis patients - are we perceiving the tip of an iceberg? Nephrol Dial Transplant. 22(2), 328–31. DOI: 10.1093/ndt/gfl534. HandelmanGJ 2007 Vitamin C deficiency in dialysis patients - are we perceiving the tip of an iceberg? Nephrol Dial Transplant. 22 2 328 31 10.1093/ndt/gfl534 Open DOISearch in Google Scholar

13. Zalba G, Fortuño A, Diez J. (2006). Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant. 21(10), 2686–90. DOI: 10.1093/ndt/gfl398. ZalbaG FortuñoA DiezJ 2006 Oxidative stress and atherosclerosis in early chronic kidney disease Nephrol Dial Transplant. 21 10 2686 90 10.1093/ndt/gfl398 Open DOISearch in Google Scholar

14. Massy ZA. (2000). Importance of homocystein, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen, and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrol Dial Transplant. 15(Suppl 5), 81–91. DOI: 10.1093/ndt/15.suppl_5.81. MassyZA 2000 Importance of homocystein, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen, and advanced glycation end-products) for atherogenesis in uraemic patients Nephrol Dial Transplant. 15 Suppl 5 81 91 10.1093/ndt/15.suppl_5.81 Open DOISearch in Google Scholar

15. Culleton BF, Bostom AG. (2000). Hyperhomocysteinemia in chronic renal disease. In: Cardiovascular Disease in End-stage Renal Failure. Loscalzo J, London GM, (eds). The Oxford University Press, New York, 2000: 211–28. CulletonBF BostomAG 2000 Hyperhomocysteinemia in chronic renal disease In: Cardiovascular Disease in End-stage Renal Failure. LoscalzoJ LondonGM (eds) The Oxford University Press New York 2000 211 28 Search in Google Scholar

16. Kielstein JT, Frölich JC, Haller H, et al. (2001). ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patient with renal disease? Nephrol Dial Transplant. 16(9), 1742–5. DOI: 10.1093/ndt/16.9.1742. KielsteinJT FrölichJC HallerH 2001 ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patient with renal disease? Nephrol Dial Transplant. 16 9 1742 5 10.1093/ndt/16.9.1742 Open DOISearch in Google Scholar

17. Lacson E, Levin NW. (2004). C-Reactive Protein and End-Stage Renal Disease. Semin Dial. 17(6), 438–48. DOI: 10.1111/j.0894-0959.2004.17604.x. LacsonE LevinNW 2004 C-Reactive Protein and End-Stage Renal Disease Semin Dial. 17 6 438 48 10.1111/j.0894-0959.2004.17604.x Open DOISearch in Google Scholar

18. Petrović D, Obrenović R, Poskurica M, i ost. (2007). Povezanost C-reaktivnog proteina sa ehokardiografskim parametrima hipertrofije i ishemijske bolesti srca u bolesnika koji se leče ponavljanim hemodijalizama. Med Pregl. LX (Suppl 2), 160–4. PetrovićD ObrenovićR PoskuricaM i ost. 2007 Povezanost C-reaktivnog proteina sa ehokardiografskim parametrima hipertrofije i ishemijske bolesti srca u bolesnika koji se leče ponavljanim hemodijalizama Med Pregl. LX Suppl 2 160 4 Search in Google Scholar

19. Akchurin OM, Kaskel F. (2015). Update on Inflammation in Chronic Kidney Disease. Blood Purif. 39(1), 84–92. DOI: 10.1159/000368940. AkchurinOM KaskelF 2015 Update on Inflammation in Chronic Kidney Disease Blood Purif. 39 1 84 92 10.1159/000368940 Open DOISearch in Google Scholar

20. Koenig W. (2003). C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. Nephrol Dial Transplant. 18(6), 1039–41. DOI: 10.1093/ndt/gfg103. KoenigW 2003 C-reactive protein and cardiovascular risk: an update on what is going on in cardiology Nephrol Dial Transplant. 18 6 1039 41 10.1093/ndt/gfg103 Open DOISearch in Google Scholar

21. Kanbay M, Perazella MA, Kasapoglu B, et al. (2010). Erythropoiesis Stimulatory Agent-Resistant Anemia in Dialysis Patients: Review of Causes and Management. Blood Purif. 29(1), 1–12. DOI: 10.1159/000245041. KanbayM PerazellaMA KasapogluB 2010 Erythropoiesis Stimulatory Agent-Resistant Anemia in Dialysis Patients: Review of Causes and Management Blood Purif. 29 1 1 12 10.1159/000245041 Open DOISearch in Google Scholar

22. Locatelli F, Canaud B, Eckardt KU, et al. (2003). Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 18(7), 1272–80. DOI: 10.1093/ndt/gfg074. LocatelliF CanaudB EckardtKU 2003 Oxidative stress in end-stage renal disease: an emerging threat to patient outcome Nephrol Dial Transplant. 18 7 1272 80 10.1093/ndt/gfg074 Open DOISearch in Google Scholar

23. Liakopoulos V, Roumeliotis S, Zarogiannis S, et al. (2019). Oxidative stress in hemodialysis: Causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 32(1), 58–71. DOI: 10.1111/sdi.12745. LiakopoulosV RoumeliotisS ZarogiannisS 2019 Oxidative stress in hemodialysis: Causative mechanisms, clinical implications, and possible therapeutic interventions Semin Dial. 32 1 58 71 10.1111/sdi.12745 Open DOISearch in Google Scholar

24. Liakopoulos V, Roumeliotis S, Bozikas A, et al. (2019). Antioxidant Supplementation in Renal Replacement Therapy Patients: Is There Evidence? Oxidative Med Cell Long. 2019, Article ID 9109473, 23 pages. DOI: 10.1155/2019/9109473. LiakopoulosV RoumeliotisS BozikasA 2019 Antioxidant Supplementation in Renal Replacement Therapy Patients: Is There Evidence? Oxidative Med Cell Long. 2019 Article ID 9109473 23 pages 10.1155/2019/9109473 Open DOISearch in Google Scholar

25. Zhang KY, Zuo L. (2014). Vitamin C supplementation in patients on maintenance dialysis. W J Clin Urol. 3(3), 344–50. DOI: 10.5410/wjcu.v3.i3.344. ZhangKY ZuoL 2014 Vitamin C supplementation in patients on maintenance dialysis W J Clin Urol. 3 3 344 50 10.5410/wjcu.v3.i3.344 Open DOISearch in Google Scholar

26. Coombes JS, Fassett RG. (2012). Antioxidant therapy in hemodialysis patients: a systematic review. Kidney Int. 81(3), 233–46. DOI: 10.1038/ki.2011.341. CoombesJS FassettRG 2012 Antioxidant therapy in hemodialysis patients: a systematic review Kidney Int. 81 3 233 46 10.1038/ki.2011.341 Open DOISearch in Google Scholar

27. Gokbel H, Atalay H, Okudan N, et al (2011). Coenzyme Q10 and its Relation with Oxidant and Antioxidant System Markers in Patients with End-Stage Renal Disease. Ren Fail. 33(7), 677–81. DOI: 10.3109/0886022X.2011.589941. GokbelH AtalayH OkudanN 2011 Coenzyme Q10 and its Relation with Oxidant and Antioxidant System Markers in Patients with End-Stage Renal Disease Ren Fail. 33 7 677 81 10.3109/0886022X.2011.589941 Open DOISearch in Google Scholar

28. Den Hoedt CH, Bots ML, Grooteman MPC, et al. (2014). Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int 86(2), 423–32. DOI: 10.1038/ki.2014.9. Den HoedtCH BotsML GrootemanMPC 2014 Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis Kidney Int 86 2 423 32 10.1038/ki.2014.9 Open DOISearch in Google Scholar

29. Panichi V, Scatena A, Rosati A, et al. (2015). High-volume online hemodiafiltration improves erythropoiesisstimulating agents (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrol Dial Transplant. 30(4): 682–9. DOI: 10.1093/ndt/gfu345. PanichiV ScatenaA RosatiA 2015 High-volume online hemodiafiltration improves erythropoiesisstimulating agents (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study Nephrol Dial Transplant. 30 4 682 9 10.1093/ndt/gfu345 Open DOISearch in Google Scholar

30. Tarng DC, Huang TP, Liu TY, et al. (2000). Effect of vitamin E-bonded membrane on the 8-hydroxy 2,-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int. 58(2), 790–9. DOI: 10.1046/j.1523-1755.2000.00228.x. TarngDC HuangTP LiuTY 2000 Effect of vitamin E-bonded membrane on the 8-hydroxy 2,-deoxyguanosine level in leukocyte DNA of hemodialysis patients Kidney Int. 58 2 790 9 10.1046/j.1523-1755.2000.00228.x Open DOISearch in Google Scholar

31. Andrulli S, Di Fillipo S, Manzoni C, et al. (2010). Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study. Nephron Clin Pract 115(1), 82–9. DOI: 10.1159/000294281. AndrulliS Di FillipoS ManzoniC 2010 Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study Nephron Clin Pract 115 1 82 9 10.1159/000294281 Open DOISearch in Google Scholar

32. Panagiotou A, Nalesso F, Zanella M, et al. Antioxidant Dialytic Approach with Vitamin E-Coated Membranes. In: Ronco C, Rosner MH. Eds. Hemodialysis: New Methods and Future Technology. Contrib Nephrol. Basel, Karger, 2011; 171: 101–6. PanagiotouA NalessoF ZanellaM Antioxidant Dialytic Approach with Vitamin E-Coated Membranes In: RoncoC RosnerMH Eds. Hemodialysis: New Methods and Future Technology. Contrib Nephrol. Basel, Karger 2011 171 101 6 Search in Google Scholar

33. Panichi V, Rosati A, Paoletti S, et al. (2011). A vitamin E-coated polysulphone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial. Blood Purif. 32(1), 7–14. DOI: 10.1159/000321369. PanichiV RosatiA PaolettiS 2011 A vitamin E-coated polysulphone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial Blood Purif. 32 1 7 14 10.1159/000321369 Open DOISearch in Google Scholar

34. Yang SK, Xiao L, Xu B, et al. (2014). Effects of vitamin E-coated dialyzer on oxidative stress and inflammation status in hemodialysis patients: a systematic review and meta-analysis. Ren Fail. 36(5), 722–31. DOI: 10.3109/0886022X.2014.890858. YangSK XiaoL XuB 2014 Effects of vitamin E-coated dialyzer on oxidative stress and inflammation status in hemodialysis patients: a systematic review and meta-analysis Ren Fail. 36 5 722 31 10.3109/0886022X.2014.890858 Open DOISearch in Google Scholar

35. Yamadera S, Nakamura Y, Inagaki M, et al. (2017). Vitamin E-Coated Dialyzer Inhibits Oxidative Stress. Blood Purif. 44(4), 288–93. DOI: 10.1159/000478971. YamaderaS NakamuraY InagakiM 2017 Vitamin E-Coated Dialyzer Inhibits Oxidative Stress Blood Purif. 44 4 288 93 10.1159/000478971 Open DOISearch in Google Scholar

36. D’Arrigo G, Baggetta R, Tripepi G, et al. (2017). Effects of vitamin E-Coated versus Conventiional Membranes in Chronic Hemodialysis Patients: A Systemic Review and Meta-Analysis. Blood Purif. 43(1–3), 101–22. DOI: 10.1159/000453444. D’ArrigoG BaggettaR TripepiG 2017 Effects of vitamin E-Coated versus Conventiional Membranes in Chronic Hemodialysis Patients: A Systemic Review and Meta-Analysis Blood Purif. 43 1–3 101 22 10.1159/000453444 Open DOISearch in Google Scholar

37. Locatelli F, Andrulli S, Vigano SM, et al. (2017). Evaluation of the Impact of a New Synthetic Vitamin EBonded Membrane on the Hypo-Responsiveness to the Erythropoietin Therapy in Hemodialysis Patients: A Multicenter Study. Blood Purif. 43(4), 338–45. DOI: 10.1159/000453442. LocatelliF AndrulliS ViganoSM 2017 Evaluation of the Impact of a New Synthetic Vitamin EBonded Membrane on the Hypo-Responsiveness to the Erythropoietin Therapy in Hemodialysis Patients: A Multicenter Study Blood Purif. 43 4 338 45 10.1159/000453442 Open DOISearch in Google Scholar

38. Fishbane S, Singh AK, Cournoyer SH, et al. (2015). Ferric pyrophosphate citrate (Triferic^™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 30(12), 2019–26. DOI: 10.1093/ndt/gfv277. FishbaneS SinghAK CournoyerSH 2015 Ferric pyrophosphate citrate (Triferic^™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients Nephrol Dial Transplant. 30 12 2019 26 10.1093/ndt/gfv277 Open DOISearch in Google Scholar

39. Gupta A, Lin V, Guss C, et al. (2015). Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int. 88(5), 1187–94. DOI: 10.1038/ki.2015.203. GuptaA LinV GussC 2015 Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients Kidney Int. 88 5 1187 94 10.1038/ki.2015.203 Open DOISearch in Google Scholar

40. Shah HH, Hazzan AD, Fishbane S. (2016). Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialys. Semin Nephrol. 36(2), 124–9. DOI: 10.1016/j.semnephrol.2016.02.007. ShahHH HazzanAD FishbaneS 2016 Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialys Semin Nephrol. 36 2 124 9 10.1016/j.semnephrol.2016.02.007 Open DOISearch in Google Scholar

41. Fishbane S, Shah HH. (2017). Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis. Hemodialysis Int. 21(Suppl 1), 104–9. DOI: 10.1111/hdi.12554. FishbaneS ShahHH 2017 Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis Hemodialysis Int. 21 Suppl 1 104 9 10.1111/hdi.12554 Open DOISearch in Google Scholar